Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chinese Natural Remedy For Coronary Heart Disease Attracts MNC Interest

This article was originally published in PharmAsia News

Executive Summary

The regenerative medicine laboratory jointly set up by the Chinese University of Hong Kong and Jinan University of Guangdong recently developed a natural remedy for treating coronary heart disease. Researchers say that the natural remedy, based on an edible Chinese herbal medicine usually consumed for headaches and urinary problems, has been tested on patients with coronary occlusion and late-stage coronary heart disease. Trial results show excellent therapeutic effects in the subjects from China, Hong Kong, Canada and the U.S. The lab plans to use the two active components extracted to develop five drugs, which are expected to launch in three years. Sources disclose that the remedy, whose intellectual property has been purchased by a Hong Kong businessman, is attracting the attention of many pharmaceutical MNCs. (Click here for more - Chinese Language)

You may also be interested in...

Who’s Hired? Four Firms Focus On Finance

A flurry of financial appointments has been seen across the off-patent industry, involving major players Dr Reddy’s, Biocon, Mayne Pharma and Xbrane Biopharma.

Aurobindo Eyes Opportunities After Offloading Natrol For $550m

Aurobindo has agreed to sell its US-based Natrol dietary supplements business at a significant premium to the $132.5m it paid in late 2014, as the Indian firm continues to drive into complex formulations in the US, including injectables and biosimilars.

GSK's Growth Drivers And Cost Containment Offset Pandemic Impact

GlaxoSmithKline’s third quarter results included a 9% decline in sales in its vaccine business, but this was offset by tight cost controls and restructuring benefits; the company expects to continue investing in its pipeline and new product launches.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts